The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates | tctmd.com
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Studying DAPT – SYNERGY Stent - Boston Scientific
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
Synergy: Short DAPT Study - ppt download
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy - ScienceDirect
